A Randomized, Open Label Study Comparing Safety and Efficacy Parameters for a High and a Low Dose of Ambrisentan (Adjusted for Body Weight) for the Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years
Phase of Trial: Phase II
Latest Information Update: 09 Oct 2019
Price : $35 *
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 27 Jun 2019 Status changed from suspended to discontinued.
- 02 Oct 2018 Planned End Date changed from 19 Nov 2018 to 1 Feb 2019.
- 02 Oct 2018 Planned primary completion date changed from 19 Nov 2018 to 1 Feb 2019.